CF patients will try anything but the side effects of Orkambi are horrible. Go to You Tube for personal experiences. The drug is also enormously expensive so Vertex is trying to force patients to stick with it.
they digested what management says and we get better ideas where things stand now and going forward...they like what they read and saw...they see the stock being cheap down here...110 by end of year is what wall street expects...vrtx owns the cf market.
Rojo, ENaC Monotherapy was not expected to yield positive clinical results in this initial Phase 2 trial, and the important outcome was 137 had a clean safety profile using it as monotherapy. The theory of clinical efficacy is based on improvements in ciliary beat frequency in combining this ENaC inhibitor with VRTX potentiator/corrector combinations in vitro. The clinical trials combining VX 137 with Orkambi or 661/kalydeco in the various subpopulations of CF mutations will proceed since that is where the positive clinical results based on the in vitro tests are most likely to show synergistic/additive clinical benefit. Obviously not every investment in acquired drug candidates pay off, but remember the Virochem acquisition, while failing to get viable hep C treatments, has succeeded in at this Canadian VRTX research lab in developing new drugs to treat IBD which are entering clinical trails this year as announced last week with a French privately held company. The cervical spinal cord injury drug candidate is another acquired drug candidate entering clinical trials this year representing a potential break through drug. Effective safe non-opiate painkillers would be medical advance to minimize the problem of addiction and dependence on opiates for chronic orthopedic pain patients suffering from failed back and neck treatments in addition to patients with pain from OA. With appropriate labelling on these drugs about avoiding overuse of OA joints when taking these drugs to prevent accelerating joint damage from uninhibited activity, in many patents, the risks of NSAIDS and opiates would certainly make VX 150 a preferable option. Lastly CRISPR program is a long shot, but a lot of companies are now pursuing gene editing technology to treat genetic disease and David Altschuler, VRTX CSO, has the expertise to collaborate with VRTX chosen partner to develop this technology as a possible cure for CF and Sickle cell disease. IMHO, its an investment worth pursing
to show any statistical benefit or improvement in FEV-1 in the Parion/ Vertex phase II CF trial alone and with saline. This result is similar to trials done with inhaled Amiloride on CF patients in the past i.e ENaC inhibitors don't work. It is a big blow for this drug development in non CF lung indication like PCD and bronchiectasis which were planned in the second half of 2016. We are paying 1.2 B for a failed drug, just like Virochem and Alios failed programs in the recent years.
VX 150 program in osteoarthritis is going to face cartilage damage issues with FDA just like JNJ/ AMGN osteoarthritis drug due to worsening joint damage after un-inhibited use of knee joint from lack of pain feelings. CRISPR program has no legs, just theory and R&D expanses. This company need to be sold.
"Persistence: Of the patients who have started on treatment, approximately 15% discontinued treatment within the first three months of initiation."
I expected much higher discontinuation than 15%. so I consider the above to be very positive even though the revenue and earnings came below analysts estimates.
Very good coverage of the pipeline. That is certainly a positive as opposed to previous reports.
Even though the expected revenue guidance was a little below previous guidance, I think it is still a very respectable sum which will hopefully makes us profitable for 2016.
1.0-1.1 billion for 2016....vs exp. 1.2-1.3b
a bit short. but i think ok for now. very much priced in and the guidance is actually not as bad as some feared. great to finally get that number from the company.
for revenue is 439.36M. Last quarter we had revenue of 417.94M
Their earnings estimate is $.29. Last quarter we had earnings of I believe $-.30
Let's hope today's figures will at least meet analysts estimates.
ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, has signed an exclusive worldwide license agreement with Vertex Pharmaceuticals Inc. (VRTX) to research, develop and commercialize novel small molecule FimH antagonists for use in the treatment of inflammatory bowel diseases (IBD).
The first clinical trials to start this year. These are the drugs being developed at VRTX Canadian research site in Laval Quebec.
I see you're scrolling the message boards, with particular emphasis on my stock
As noted above, I do have a position in VRTX.
However, I have NO position in ARNA, nor do I have any plans to take a position
in a diet pill company.
Tnorman200....this board is full of card sharps and crapshooters. Find and post good research and avoid #$%$ matches with them. That just keeps their posts near the top. I assume you sold ICPT to invest in ARNA. I would say good move, but you have to know facts, many of which are buried on this board. You want to find posts with high thumbs up and people willing to state a positive long term sentiment. If you post facts, others appreciating them will keep them near the top of the heap.
Sentiment: Strong Buy
Will fill the gap down to 64 for sure but even that won't hold. Still time to short but sad to see. Hopefully the new research kid will take the company in a new direction doing what it does best but only a matter of time before some significant down-sizing. The hedge guy is only looking to parachute into Martha's.